CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Fludarabine +3 moredrug
Likely dose
Fludarabine 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00448019
NCT00448019Phase 2Completed
CompareCT.gov

Fludarabine, Cyclophosphamide, Rituximab and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center·interventional·Posted Mar 15, 2007·Updated Nov 2, 2015

In Brief

A Phase 2 clinical trial evaluating Fludarabine, Cyclophosphamide, and 2 other interventions for Chronic Lymphocytic Leukemia. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if the combination of fludarabine, cyclophosphamide, rituximab, and bevacizumab is effective in treating chronic lymphocytic leukemia in patients who have already been treated with chemotherapy. The safety of this treatment will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 15, 2007
Enrollment StartFeb 1, 2007
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.7 yearsPosted 19.3 years ago

Interventions

Fludarabinedrug

25 mg/m\^2 IV over 30 minutes daily for 3 days

Cyclophosphamidedrug

250 mg/m\^2 IV over 30 minutes daily for 3 days

Rituximabdrug

375 mg/m\^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m\^2 IV 30-minute infusion.

Bevacizumabdrug

10 mg/Kg IV on Day 3, course 1 over 30-90 minutes